Journal article
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
- Abstract:
-
Background and Aims Thromboxane (TX) A2, released by activated platelets, plays an important role in atherothrombosis. Urinary 11-dehydro-TXB2 (U-TXM), a stable metabolite reflecting the whole-body TXA2 biosynthesis, is reduced by ∼70% by daily low-dose aspirin. The U-TXM represents a non-invasive biomarker of in vivo platelet activation and is enhanced in patients with diabetes. This study assessed whether U-TXM is associated with t...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.1093/eurheartj/ehad868
Funding
Bibliographic Details
- Publisher:
- Oxford University Press
- Journal:
- European Heart Journal More from this journal
- Volume:
- 45
- Issue:
- 15
- Pages:
- 1355–1367
- Publication date:
- 2024-02-22
- Acceptance date:
- 2023-12-19
- DOI:
- EISSN:
-
1522-9645
- ISSN:
-
0195-668X
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1577609
- Local pid:
-
pubs:1577609
- Deposit date:
-
2023-12-04
Terms of use
- Copyright holder:
- Petrucci et al.
- Copyright date:
- 2024
- Rights statement:
- © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record